Autoimmune hypothesis

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

Theory[edit | edit source]

The Open Medicine Foundation, with immunologist Mark Davis, and geneticist Lars Steinmetz, is currently investigating the replication of T cells in ME, which may indicate an autoimmune disease is present in some ME/CFS patients.[1]HLA gene associations are a possible hallmark of autoimmune disease, and were investigated by Fluge et al. in 2020.[2]

Evidence[edit | edit source]

ME/CFS can cause a number of immune symptoms including a sore throat, swollen lymph nodes, and flu-like symptoms.[3][4]

Evidence for autoimmunity in ME and CFS[edit | edit source]

Shows fibromyalgia 30-77% overlap, Hashimoto's thyroiditis 17-20%, POTS 11-40% overlap and family history of autoimmune conditions 18-41% overlap.
Autoimmune conditions in people with ME/CFS. Source: Sotzny et al (2018), EUROMENE project.

Many people with ME/CFS also have autoimmune conditions such as Hashimoto's thyroiditis, or have a family history of autoimmune diseases.[5]POTS, or postural orthostatic tachycardia syndrome, can be initiated or maintained by autoantibodies as well, and POTS is common in people with ME. A number of different immune system abnormalities have been found in some patients with ME/CFS.[5]

One study found elevated cellular antigens in 83% of CFS patients.[6]

Autoimmune disease is one of several illnesses or conditions experienced alongside of ME/CFS.[7]

Samples from a large cohort (n=268) in Berlin, Germany and a smaller sample of patients treated with Rituximab (n=25) were measured against controls (n=168). Researchers found that antibodies against a neurotransmitter receptor were elevated in 29.5% of patients. Specifically, antibodies to ß2 adrenergic and M3 and M4 muscarinic cholinergic receptors, which are both G protein-coupled receptors (GCPRs). In patients receiving Rituximab, those who were responders had significantly lower levels of ß2 and M4 autoantibodies after treatment. The authors suggest that these autoantibodies could be biomarkers to those CFS patients most likely to respond to Rituximab treatment.[8][9]

Notable studies[edit | edit source]

Talks and interviews[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.01.1 Open Medicine Foundation (February 28, 2018). "OMF-funded research: T cells and molecular immunology". Open Medicine Foundation. Retrieved July 11, 2019.
  2. 2.02.1 Lande, Asgeir; Fluge, Øystein; Strand, Elin B.; Flåm, Siri T.; Sosa, Daysi D.; Mella, Olav; Egeland, Torstein; Saugstad, Ola D.; Lie, Benedicte A. (March 24, 2020). "Human Leukocyte Antigen alleles associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)". Scientific Reports. 10 (1): 1–8. doi:10.1038/s41598-020-62157-x. ISSN 2045-2322.
  3. Carruthers, BM; van de Sande, MI; De Meirleir, KL; Klimas, NG; Broderick, G; Mitchell, T; Staines, D; Powles, ACP; Speight, N; Vallings, R; Bateman, L; Bell, DS; Carlo-Stella, N; Chia, J; Darragh, A; Gerken, A; Jo, D; Lewis, DP; Light, AR; Light, KC; Marshall-Gradisnik, S; McLaren-Howard, J; Mena, I; Miwa, K; Murovska, M; Stevens, SR (2012), Myalgic encephalomyelitis: Adult & Paediatric: International Consensus Primer for Medical Practitioners (PDF), ISBN 978-0-9739335-3-6
  4. Fukuda, K.; Straus, S. E.; Hickie, I.; Sharpe, M. C.; Dobbins, J. G.; Komaroff, A. (December 15, 1994). "The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group" (PDF). Annals of Internal Medicine. American College of Physicians. 121 (12): 953–959. ISSN 0003-4819. PMID 7978722.
  5. 5.05.15.2 Sotzny, Franziska; Blanco, Julià; Capelli, Enrica; Castro-Marrero, Jesús; Steiner, Sophie; Murovska, Modra; Scheibenbogen, Carmen (2018), "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease", Autoimmunity Reviews, 17 (6): 601-609, doi:10.1016/j.autrev.2018.01.009
  6. von Mikecz, A.; Konstantinov, K.; Buchwald, D. S.; Gerace, L.; Tan, E. M. (February 1997). "High frequency of autoantibodies to insoluble cellular antigens in patients with chronic fatigue syndrome". Arthritis and Rheumatism. 40 (2): 295–305. ISSN 0004-3591. PMID 9041942.
  7. "Overlapping Conditions – American ME and CFS Society". ammes.org. Retrieved August 12, 2018.
  8. "Autoantibodies found in subset of CFS patients | #MEAction". MEAction. Retrieved August 12, 2018.
  9. Loebel, Madlen; Grabowski, Patricia; Heidecke, Harald; Bauer, Sandra; Hanitsch, Leif G.; Wittke, Kirsten; Meisel, Christian; Reinke, Petra; Volk, Hans-Dieter (February 2016). "Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome". Brain, Behavior, and Immunity. 52: 32–39. doi:10.1016/j.bbi.2015.09.013. ISSN 1090-2139. PMID 26399744.
  10. Bynke, Annie; Julin, Per; Gottfries, Carl-Gerhard; Heidecke, Harald; Scheibenbogen, Carmen; Bergquist, Jonas (August 1, 2020). "Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts". Brain, Behavior, & Immunity - Health. 7: 100107. doi:10.1016/j.bbih.2020.100107. ISSN 2666-3546.
  11. Blomberg, Jonas; Gottfries, Carl-Gerhard; Elfaitouri, Amal; Rizwan, Muhammad; Rosén, Anders (February 15, 2018). "Infection Elicited Autoimmunity and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: An Explanatory Model". Frontiers in Immunology. 9. doi:10.3389/fimmu.2018.00229. ISSN 1664-3224. PMC 5818468. PMID 29497420.
  12. "Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - Full Text View". clinicaltrials.gov. Retrieved April 25, 2020.
  13. Morris, Gerwyn; Berk, Michael; Galecki, Piotr; Maes, Michael (April 1, 2014). "The Emerging Role of Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/cfs)". Molecular Neurobiology. 49 (2): 741–756. doi:10.1007/s12035-013-8553-0. ISSN 1559-1182.
  14. Maes, Michael; Ringel, Karl; Kubera, Marta; Anderson, George; Morris, Gerwyn; Galecki, Piotr; Geffard, Michel (September 5, 2013). "In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation". Journal of Affective Disorders. 150 (2): 223–230. doi:10.1016/j.jad.2013.03.029. ISSN 0165-0327.
  15. Maes, Michael; Ringel, Karl; Kubera, Marta; Berk, Michael; Rybakowski, Janusz Rybakowski (February 1, 2012). "Increased autoimmune activity against 5-HT : a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression". Journal of affective disorders. 136 (3): 386–392. doi:10.1016/j.jad.2011.11.016. ISSN 0165-0327.
  16. Staines, Donald R (May 1, 2004). "Is chronic fatigue syndrome an autoimmune disorder of endogenous neuropeptides, exogenous infection and molecular mimicry?". Medical Hypotheses. 62 (5): 646–652. doi:10.1016/j.mehy.2004.01.012. ISSN 0306-9877.

immunologist A clinical immunologist is medical doctor specializing immune system problems that lead to infections, immunodeficiency disorders, autoimmune diseases, and autoinflammatory diseases including anaphylaxis ans allergies

myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

tachycardia An unusually rapid heart beat. Can be caused by exercise or illness. A symptom of postural orthostatic tachycardia syndrome (POTS). (Learn more: www.heart.org)

autoantibody An antibody that works against the body's own antigens, a hallmark of autoimmune diseases. Autoantibodies are the opposite of an antibodies.

postural orthostatic tachycardia syndrome (POTS) - A form of orthostatic intolerance where the cardinal symptom is excessive tachycardia due to changing position (e.g. from lying down to sitting up).

antibodies Antibodies or immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

autoantibody An antibody that works against the body's own antigens, a hallmark of autoimmune diseases. Autoantibodies are the opposite of an antibodies.

β β / Β. Greek letter beta (symbol), equivalent to "b".

myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.